Aspen, Colo. — At the summer edition of The Cosmetic Bootcamp (CBC), attendees learned about new neuromodulators that are likely to join Botox, Dysport and Xeomin on the US market.
PrabobotulinumtoxinA (Nabota, Daewoong/Evolus) earned South Korean regulatory approval in 2013. This neuromodulator differs from onabotulinumtoxinA structurally, said Kenneth Beer, M.D., and in the design of its pivotal American and Canadian/European trials. These data are now under regulatory review in their respective markets.
In the American EV-001 and EV-002 trials, 67% and 71% of patients achieved improvements of at least 2 points on the 4-point Glabellar Line Scale (GLS) 30 days post-treatment. Improvements of at least 2 points lasted 120 days for around 10% of patients in each study.
The Canadian/European EVB-003 trial included 540 patients total. At day 30, 87.2%, 82.8% and 4.2% of patients in the prabobotulinumtoxinA, onabotulinumtoxinA and placebo cohorts, respectively, achieved GLS scores of zero or one at maximum frown.
Dr. Beer is associate clinical professor of dermatology at the University of Miami Miller School of Medicine, consulting associate with Duke University, clinical associate in dermatology, University of Pennsylvania Perelman School of Medicine and a CBC cofounder.
For additional details or to register for future CBC events, please contact:
CBC/Meeting Designs, LLC